GlobeNewswire Inc | Oct 7, 2021 08:00AM EDT

October 07, 2021

PALO ALTO, Calif. and AUSTIN, Texas, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Genoox, the worlds largest community-driven genomic data platform, and Aspira Womens Health Inc. (Aspira) (Nasdaq: AWH), a bioanalytical-based womens health company, today announced a partnership to develop solutions to advance women's health with rapid results, diagnosis, and insights.

Currently, the majority of genetic sequencing information can be found across multiple databases which can limit the ability for medical professionals to access and analyze this important data. Without advanced data aggregation and analytics that inform machine learning (ML) and artificial intelligence (AI) algorithms, it is more difficult to detect early-stage diseases as well as monitor and treat patients effectively. Genooxs global platform brings together information available in the public domain on one platform, allowing for the complete analysis of the data and better patient care. Aspira plans to leverage this knowledge base to expand on its proprietary algorithm development across multiple product lines.

Aspira, an innovative womens health company, has forged a partnership with Genoox aimed toward enabling new test development fueled by groundbreaking data solutions. Aspira plans to continue to leverage its extensive biobank, and with the addition of this partnership plans to expand its wealth of data to aid in test discovery and validation. Additionally, both Genoox and Aspira anticipate expanding their product offerings to meet market demands.

Aspiras dedication to womens health has increased the risk assessments available to women who are at risk for diseases like ovarian cancer and other pelvic diseases, said Amir Trabelsi, CEO, and co-founder of Genoox. This partnership will provide medical professionals with further information and tools to help women going through the most difficult periods of their lives, and also help both Genoox and Aspira expand our contributions to the medical and genomics industries.

Valerie Palmieri, President and CEO of Aspira, added, Genooxs tremendous AI and ML capabilities will enhance our data and biobank platform to expand our value proposition for our patients. Genoox and Aspira each seek to tackle the most difficult diseases in womens health, and this platform should allow us to reduce the development time for potentially groundbreaking data solutions. Additionally, with this partnership, we are one step closer to our goal of closing the gap in ovarian cancer risk assessment and developing solutions for pelvic diseases combining genomics with proteomics. We are honored to be working alongside Genoox in advancing womens health.

About Genoox

Genoox harnesses the power of its community to enable actionable insights from the largest real time-real life genomic database serving professionals at the point of care. Genooxs cloud-based AI platform, Franklin, connects clinicians, genetic counsellors and healthcare organizations, while enabling platform users to make impactful discoveries using the most advanced genomic tools and applications. Genoox is used by over 1,700 health organizations, hospitals and medical facilities in 44 markets across the globe. Visit our website for more information at: www.genoox.com.

About ASPIRA Womens Health Inc.Aspira Womens Health Inc. (formerly known as Vermillion, Inc., Nasdaq: VRML) is transforming womens health with the discovery, development, and commercialization of innovative testing options and bioanalytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women. Aspira Womens Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases, such as pelvic mass risk assessment and endometriosis detection. OVA1 plus combines our FDA-cleared products, OVA1 and OVERA, to detect risk of ovarian malignancy in women with adnexal masses. ASPIRA GenetiXSM testing offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, Aspira Womens Health has expertise in cutting edge research to inform our next generation of products. Our focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection and optimize treatment plans. The next generation of products in development are OVASight and EndoCheckTM. Visit www.aspirawh.com for more information

Forward-Looking StatementsThis press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the expected benefits of combining Aspiras biobank with Genooxs genomic database and the ability for this combined database to facilitate faster test development and expand Aspiras product portfolio. These statements involve a number of risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements. Words such as may, expects, intends, anticipates, believes, estimates, plans, seeks, could, should, continue, will, potential, projects, and similar expressions are intended to identify forward-looking statements. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties, and assumptions, including the risks and uncertainties described in the section entitled Risk Factors in Aspira Womens Healths Annual Report on Form 10-K for the year ended December 31, 2020 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2021. The events and circumstances reflected in Aspira Womens Healths forward-looking statements may not be achieved or occur, and actual results could differ materially from those contemplated by the forward-looking statements. Aspira Womens Health expressly disclaims any obligation to update, amend, or clarify any forward-looking statements to reflect events, new information, or circumstances occurring after the date of this press release, except as required by law.

Media Contact, GenooxShahni Ben-Haim NYGCshahni@now-you.co.il

Investor Relations Contact, Aspira Womens Health Inc.

Ashley R. Robinson LifeSci Advisors, LLC Tel 617-430-7577Arr@lifesciadvisors.com